骨髓纤维化异基因造血细胞移植的真实世界视角
骨髓纤维化(MF)是异质性克隆性干细胞肿瘤,异基因造血干细胞移植(HSCT)是重要治愈手段。本文综述当前实践,包括JAK抑制剂作用、白血病转化前后移植数据,并提出临床-分子预后模型以优化移植时机。
要点
- HSCT是原发MF及ET/PV后MF或继发MF的治愈选择,但死亡风险高需严格筛选。
- JAK抑制剂在移植前后的作用被纳入当前实践综述。
- 提出临床-分子预后模型辅助确定HSCT最佳时间点。
核心结论
- 异基因HSCT为MF提供治愈可能,但需通过风险分层和患者选择优化时机。
研究设计与样本
- 综述性文章,总结当前MF移植实践及临床-分子预后模型。
主要发现
- MF病程从惰性到高度进展不等,可通过患者临床特征及分子遗传谱进行死亡风险分层。
临床怎么用
- 利用风险分层工具和提出的临床-分子预后模型,个体化确定HSCT考虑时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-established molecular drivers. Allogeneic haematopoietic stem cell transplantation (HSCT) offers an important curative treatment option for primary MF and post-essential thrombocythaemia/polycythaemia vera MF or secondary MF. With a disease course that varies from indolent to highly progressive, we are now able to stratify risk of mortality through various tools including patient-related clinical characteristics as well as molecular genetic profile. Owing to the high risk of mortality and morbidity associated with HSCT for patients with myelofibrosis, it is important to improve patient selection for transplant. Our primary goal is to comprehensively define our understanding of current practices including the role of Janus Kinase (JAK) inhibitors, to present the data behind transplantation before and after leukaemic transformation, and to introduce novel personalization of MF treatment with a proposed clinical-molecular prognostic model to help elucidate a timepoint optimal for consideration of HSCT.
引用
- Savani M, Dulery R, Bazarbachi AH, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective. Br J Haematol. 2021. PMID: 33881169. doi:10.1111/bjh.17469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。